Maeve Mullooly

1.7k total citations
49 papers, 1.2k citations indexed

About

Maeve Mullooly is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Maeve Mullooly has authored 49 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 17 papers in Cancer Research and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Maeve Mullooly's work include Breast Cancer Treatment Studies (17 papers), Global Cancer Incidence and Screening (16 papers) and HER2/EGFR in Cancer Research (12 papers). Maeve Mullooly is often cited by papers focused on Breast Cancer Treatment Studies (17 papers), Global Cancer Incidence and Screening (16 papers) and HER2/EGFR in Cancer Research (12 papers). Maeve Mullooly collaborates with scholars based in Ireland, United States and United Kingdom. Maeve Mullooly's co-authors include Michael J. Duffy, John Crown, Patricia M. McGowan, Norma O’Donovan, Gretchen L. Gierach, Mark E. Sherman, Ruth M. Pfeiffer, Louise A. Brinton, Babak Ehteshami Bejnordi and Nico Karssemeijer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Maeve Mullooly

46 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maeve Mullooly Ireland 17 614 343 291 264 213 49 1.2k
Hanne A. Askautrud Norway 12 563 0.9× 317 0.9× 346 1.2× 227 0.9× 246 1.2× 22 1.3k
Rachel L. Stewart United States 15 342 0.6× 384 1.1× 111 0.4× 281 1.1× 117 0.5× 31 942
Islam M. Miligy United Kingdom 21 506 0.8× 435 1.3× 127 0.4× 416 1.6× 116 0.5× 47 1.0k
Xingrui Li China 16 298 0.5× 381 1.1× 246 0.8× 290 1.1× 182 0.9× 45 1.1k
Robin Edwards United States 12 492 0.8× 493 1.4× 205 0.7× 219 0.8× 195 0.9× 25 1.1k
Yunn-Yi Chen United States 14 406 0.7× 377 1.1× 158 0.5× 340 1.3× 64 0.3× 20 1.2k
Shaolei Lu United States 22 474 0.8× 582 1.7× 132 0.5× 274 1.0× 46 0.2× 81 1.4k
Maurizio Di Bonito Italy 26 794 1.3× 870 2.5× 372 1.3× 736 2.8× 150 0.7× 82 2.0k
Vilppu J. Tuominen Finland 12 285 0.5× 295 0.9× 154 0.5× 164 0.6× 189 0.9× 13 816
Elizabeth Pinney United Kingdom 11 816 1.3× 156 0.5× 125 0.4× 364 1.4× 269 1.3× 12 1.1k

Countries citing papers authored by Maeve Mullooly

Since Specialization
Citations

This map shows the geographic impact of Maeve Mullooly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maeve Mullooly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maeve Mullooly more than expected).

Fields of papers citing papers by Maeve Mullooly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maeve Mullooly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maeve Mullooly. The network helps show where Maeve Mullooly may publish in the future.

Co-authorship network of co-authors of Maeve Mullooly

This figure shows the co-authorship network connecting the top 25 collaborators of Maeve Mullooly. A scholar is included among the top collaborators of Maeve Mullooly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maeve Mullooly. Maeve Mullooly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burke, A., Mustapha Abubakar, Kathleen Bennett, et al.. (2025). A systematic review of determinants of breast cancer risk among women with benign breast disease. npj Breast Cancer. 11(1). 16–16. 1 indexed citations
2.
Zhang, Mengyang, et al.. (2025). Modelling the impact of the COVID-19 pandemic on cancer stage migration and excess mortality in Ireland. Preventive Medicine Reports. 52. 103020–103020. 2 indexed citations
3.
Murphy, S, Niall Phelan, Alan Р. Smith, et al.. (2025). Evaluation of recall rates in the Irish national breast screening programme: Insights from two million screening mammograms. European Journal of Radiology. 189. 112179–112179. 1 indexed citations
4.
Harvey, Harry, Claire Brady, Seán J. Costelloe, et al.. (2024). Dealing with digital paralysis: Surviving a cyberattack in a National Cancer center. Journal of Cancer Policy. 39. 100466–100466. 7 indexed citations
5.
6.
Pan, Kathy, Rebecca A. Nelson, Rowan T. Chlebowski, et al.. (2024). Ductal carcinoma in situ and cause-specific mortality among younger and older postmenopausal women: the Women’s Health Initiative. Breast Cancer Research and Treatment. 207(1). 65–79.
7.
Abubakar, Mustapha, Maeve Mullooly, Sarah J. Nyante, et al.. (2022). Mammographic Density Decline, Tamoxifen Response, and Prognosis by Molecular Characteristics of Estrogen Receptor–Positive Breast Cancer. JNCI Cancer Spectrum. 6(3). 2 indexed citations
8.
Mullooly, Maeve, Shaoqi Fan, Ruth M. Pfeiffer, et al.. (2019). Using Digital Pathology to Understand Epithelial Characteristics of Benign Breast Disease among Women Undergoing Diagnostic Image-Guided Breast Biopsy. Cancer Prevention Research. 12(12). 861–870. 1 indexed citations
9.
Mullooly, Maeve, Diana R. Withrow, Rochelle E. Curtis, et al.. (2019). Association of lifestyle and clinical characteristics with receipt of radiotherapy treatment among women diagnosed with DCIS in the NIH-AARP Diet and Health Study. Breast Cancer Research and Treatment. 179(2). 445–457. 1 indexed citations
10.
Oh, Hannah, Ruth M. Pfeiffer, Roni T. Falk, et al.. (2019). Relationship of circulating insulin-like growth factor-I and binding proteins 1–7 with mammographic density among women undergoing image-guided diagnostic breast biopsy. Breast Cancer Research. 21(1). 81–81. 12 indexed citations
11.
Shaikh, Asim Jamal, Maeve Mullooly, Shahin Sayed, et al.. (2018). Mammographic Breast Density and Breast Cancer Molecular Subtypes: The Kenyan-African Aspect. BioMed Research International. 2018. 1–10. 16 indexed citations
12.
Mullooly, Maeve, Jeanne Murphy, Gretchen L. Gierach, et al.. (2017). Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004–2013): Amassing data from independent Western populations provide etiologic clues. European Journal of Cancer. 86. 326–333. 27 indexed citations
13.
Bejnordi, Babak Ehteshami, Jimmy Lin, Maeve Mullooly, et al.. (2017). Deep learning-based assessment of tumor-associated stroma for diagnosing breast cancer in histopathology images. PubMed. 2017. 929–932. 56 indexed citations
14.
Caiazza, Francesco, Patricia M. McGowan, Maeve Mullooly, et al.. (2015). Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. British Journal of Cancer. 112(12). 1895–1903. 47 indexed citations
15.
Mullooly, Maeve, Dylan Conklin, Patricia M. McGowan, et al.. (2015). Neratinib to inhibit the growth of triple-negative breast cancer cells.. Journal of Clinical Oncology. 33(15_suppl). 1099–1099. 8 indexed citations
16.
Synnott, Naoise C., Maeve Mullooly, Francesco Caiazza, et al.. (2014). Mutant p53: A therapeutic target for the treatment of triple-negative breast cancer?. Journal of Clinical Oncology. 32(15_suppl). 1118–1118. 1 indexed citations
17.
Canonici, Alexandra, Merel Gijsen, Maeve Mullooly, et al.. (2013). Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 4(10). 1592–1605. 137 indexed citations
18.
McGowan, Patricia M., Maura B. Cotter, Maeve Mullooly, et al.. (2013). Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Cancer Biology & Therapy. 14(6). 537–545. 30 indexed citations
19.
Mullooly, Maeve, Stephen F. Madden, E. W. M. McDermott, et al.. (2011). P3-17-03: ADAM17: A Novel Therapeutic Target for Treatment of Triple Negative Breast Cancer.. Cancer Research. 71(24_Supplement). P3–17. 1 indexed citations
20.
Duffy, Michael J., et al.. (2011). The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?. Clinical Proteomics. 8(1). 9–9. 163 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hanne A. Askautrud Breakdown of academic impact, for papers by Rachel L. Stewart Breakdown of academic impact, for papers by Islam M. Miligy Breakdown of academic impact, for papers by Xingrui Li Breakdown of academic impact, for papers by Robin Edwards Breakdown of academic impact, for papers by Yunn-Yi Chen Breakdown of academic impact, for papers by Shaolei Lu Breakdown of academic impact, for papers by Maurizio Di Bonito Breakdown of academic impact, for papers by Vilppu J. Tuominen Breakdown of academic impact, for papers by Elizabeth Pinney
Rankless by CCL
2026